Composition for predicting risk of developing liver cancer

MYPI2025004293A0Undetermined Publication Date: 2024-07-26LEPIDYNE CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025004293
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-01-26
Filing Date
2024-01-24
Publication Date
2024-07-26

AI Technical Summary

Technical Problem

Current methods for early detection of liver cancer are inadequate, leading to late-stage diagnoses and varying survival rates, with a need for non-invasive and accurate predictive tools to improve screening efficiency and patient outcomes.

Method used

A composition that utilizes specific biomarkers, including CpG sites on human chromosomes 12, 17, and 19, to measure methylation levels in blood-derived cell-free DNA, enabling early detection of liver cancer through liquid biopsy, employing primers that differentiate between methylated and unmethylated DNA for sensitive and specific methylation analysis.

Benefits of technology

This approach significantly increases the accuracy of liver cancer risk prediction, enhances early diagnosis sensitivity, and improves patient survival rates by providing a non-invasive, minimally invasive method for continuous monitoring without radiation exposure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025004293_DRAWING_001
    Figure PI2025004293_DRAWING_001
  • Figure PI2025004293_DRAWING_002
    Figure PI2025004293_DRAWING_002
  • Figure PI2025004293_DRAWING_003
    Figure PI2025004293_DRAWING_003
Patent Text Reader

Abstract

The present application relates to a composition for predicting a risk of developing liver cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Composition for predicting the risk of developing liver cancer

[0001] The present application relates to a composition for predicting the risk of developing liver cancer.

[0002] Although the countless cells in the human body possess the same DNA sequence, their morphology and function vary greatly. This is because each cell expresses specific genes and undergoes distinct differentiation processes, resulting in an independent phenotype. This cell-specific gene expression variation is driven by various factors, including DNA methylation, histone modification, and tissue-specific transcription factors.

[0003] Liquid biopsy is a method of obtaining and examining a sample through non-invasive or minimally invasive means. It places less burden on the subject than the existing tissue biopsy, allows for continuous monitoring through frequent examinations, and does not have the risk of radiation exposure, which is a side effect of imaging methods.

[0004] Cancer patient survival rates vary significantly depending on the stage of the disease at diagnosis, and early detection and treatment can guarantee high survival rates. Liver cancer is currently showing an increasing incidence worldwide, and the majority of patients are diagnosed at a later stage. Therefore, the development of methods for early diagnosis of liver cancer is considered a technology with significant social and economic benefits.

[0005] An example of the present application is to provide a composition for predicting the risk of developing liver cancer or a method for providing information for predicting the risk of developing liver cancer, wherein the composition can predict the risk of developing liver cancer using a liver cancer-specific biomarker and the marker can be detected in blood-derived cell-free DNA (cfDNA).

[0006] An example of the present application relates to a composition for predicting the risk of developing liver cancer, comprising an agent capable of measuring the methylation level of at least one of the CpG sites included in a sequence region 21810279 to 21810792 of human chromosome 12, a sequence region 29298021 to 29298631 of human chromosome 17, or a sequence region 19738547 to 19739846 of human chromosome 19 in a biological sample.

[0007] Another example of the present application relates to a method for providing information for predicting the risk of developing liver cancer, or a method for predicting the risk of developing liver cancer, comprising the step of measuring the methylation level of at least one of the CpG sites included in the sequence region 21810279 to 21810792 of human chromosome 12, the sequence region 29298021 to 29298631 of human chromosome 17, or the sequence region 19738547 to 19739846 of human chromosome 19 in a biological sample isolated from a subject.

[0008]

[0009] Hereinafter, the present application will be described in more detail.

[0010] As used herein, the term "methylation" refers to the attachment of a methyl group to a base constituting DNA. For example, methylation may occur at a cytosine at a specific CpG site in a specific gene or nucleic acid.

[0011] As used herein, the term “methylation status” or “methylation state” refers to whether a cytosine at a specific CpG site of a specific gene or nucleic acid is methylated. Specifically, it refers to the presence or absence of 5-methyl-cytosine at one or more CpG dinucleotides within a base sequence. For example, it may refer to whether a cytosine at one or more CpG sites included in the sequence represented by SEQ ID NO: 1, the sequence represented by SEQ ID NO: 2, or the sequence represented by SEQ ID NO: 3 is methylated.

[0012] As used herein, the term “methylation level” or “methylation degree” means the amount of methylation present in a base sequence within the sequence represented by SEQ ID NO: 1, the sequence represented by SEQ ID NO: 2, or the sequence represented by SEQ ID NO: 3.

[0013] As used herein, the term "CpG site" or "CpG sequence" refers to a CpG site present in the base sequence of a specific gene or nucleic acid. The gene is a concept that includes a series of structural units that are necessary for expression and are operably linked to each other, and may include, for example, a promoter region, a protein coding region (open reading frame, ORF), and a terminator region. Accordingly, the CpG site may be present in the promoter region, protein coding region (open reading frame, ORF), or terminator region of the gene. For example, it may be a CpG site present in the promoter region of the gene.

[0014] The term “nucleic acid” as used herein refers to a polymer of nucleotides, such as ribonucleotides or deoxyribonucleotides, and includes polynucleotides, oligonucleotides, oligomers, oligos, coding sequences, and the like. The nucleic acid may be used to mean single-, double-, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers having purine and pyrimidine bases, or other natural, chemically, or biochemically modified, unnatural, or derivatized nucleotide bases. For example, the nucleic acid may be a nucleic acid comprising at least one CpG site included in a nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, and having a contiguous portion of a nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. As an example, the nucleic acid may be a nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

[0015] When this specification describes a component as “comprising” or “including,” this does not exclude other components, but rather includes other components, unless otherwise specifically stated.

[0016] Unless otherwise indicated herein, nucleic acids are described in a left-to-right, 5' to 3' orientation, respectively.

[0017] In this specification, the singular includes plural references unless the context clearly dictates otherwise.

[0018] An example of the present application relates to a composition for predicting the risk of developing liver cancer, comprising an agent capable of measuring the methylation level of at least one CpG site included in a sequence region 21810279 to 21810792 of human chromosome 12, a sequence region 29298021 to 29298631 of human chromosome 17, or a sequence region 19738547 to 19739846 of human chromosome 19 in a biological sample.

[0019] Specifically, a composition according to an example of the present application may further comprise an agent capable of measuring a methylation level of at least one CpG site included in a sequence region 21810279 to 21810792 of human chromosome 12 in a biological sample, an agent capable of measuring a methylation level of at least one CpG site included in a sequence region 29298021 to 29298631 of human chromosome 17; and / or an agent capable of measuring a methylation level of at least one CpG site included in a sequence region 19738547 to 19739846 of human chromosome 19. According to the present invention, as a result of measuring all of the methylation level of at least one CpG site included in the sequence region 21810279 to 21810792 of the human chromosome 12, the methylation level of at least one CpG site included in the sequence region 29298021 to 29298631 of the human chromosome 17, and / or the methylation level of at least one CpG site included in the sequence region 19738547 to 19739846 of the human chromosome 19, tumor coverage was further improved, thereby increasing the accuracy of liver cancer risk prediction.

[0020] The composition may further comprise an agent capable of measuring the concentration of alpha fetoprotein (AFP) in the biological sample.

[0021] The above sequence region may be included in cell free DNA (cfDNA).

[0022] A “biomarker” or “marker” according to an example of the present application is a general term for a nucleic acid comprising at least one CpG site included in a sequence region 21810279 to 21810792 of human chromosome 12, a sequence region 29298021 to 29298631 of human chromosome 17, or a sequence region 19738547 to 19739846 of human chromosome 19.

[0023] At least one CpG site included in the sequence region 21810279 to 21810792 of the human chromosome 12 is a CpG site located in the sequence 21810279 to 21810280 of the human chromosome 12, a CpG site located in the sequence 21810450 to 21810451, a CpG site located in the sequence 21810458 to 21810459, a CpG site located in the sequence 21810489 to 21810490, a CpG site located in the sequence 21810600 to 21810601, a CpG site located in the sequence 21810750 to 21810751, a CpG site located in the sequence 21810759 to 21810760, and It may be at least one selected from the group consisting of CpG sites located at sequences 21810791 to 21810792, and may include, for example, a CpG site located at sequences 21810750 to 21810751 of human chromosome 12. The sequence region 21810279 to 21810792 of human chromosome 12 may have a sequence represented by SEQ ID NO: 1. In the present specification, a nucleic acid including at least one CpG site included in the sequence region 21810279 to 21810792 of human chromosome 12 is referred to as “marker 1” or “marker 1”. The nucleic acid may have a continuous partial sequence of the sequence region.For example, the sequence region 21810279 to 21810792 of the human chromosome 12 is specifically the sequence region 21810279 to 21810760 of the human chromosome 12, the sequence region 21810279 to 21810751, the sequence region 21810450 to 21810792, the sequence region 21810450 to 21810760, the sequence region 21810450 to 21810751, the sequence region 21810458 to 21810792, the sequence region 21810458 to 21810760, the sequence region 21810458 to 21810751, the sequence region 21810489 to It may be the 21810792nd sequence region, the 21810489 to 21810760th sequence region, the 21810489 to 21810751st sequence region, the 21810600 to 21810792nd sequence region, the 21810600 to 21810760th sequence region, the 21810600 to 21810751st sequence region, the 21810750 to 21810792nd sequence region, the 21810750 to 21810760th sequence region, or the 21810750 to 21810751st sequence region.

[0024] At least one CpG site included in the sequence region 29298021 to 29298631 of the human chromosome 17 may include a CpG site located in the sequence region 29298115 to 29298116, 29298118 to 29298119, 29298124 to 29298125, 29298136 to 29298137, 29298142 to 29298143, or 29298184 to 29298185 of the human chromosome 17. The sequence region 29298021 to 29298631 of the human chromosome 17 may be represented by SEQ ID NO: 2. In this specification, a nucleic acid comprising at least one CpG site within the sequence region 29298021 to 29298631 of the human chromosome 17 is referred to as “marker 2”. The nucleic acid may have a continuous partial sequence of the sequence region.

[0025] At least one CpG site included in the sequence region 19738547 to 19739846 of the human chromosome 19 may include a CpG site located in the sequence 19739407 to 19739408 of the human chromosome 19. The sequence region 19738547 to 19739846 of the human chromosome 19 may be represented by SEQ ID NO: 3. In the present specification, a nucleic acid including at least one CpG site included in the sequence region 19738547 to 19739846 of the human chromosome 19 is referred to as “marker 3”. The nucleic acid may have a continuous partial sequence of the sequence region.

[0026] In one example of the present application, a “target methylation site” is a site of interest for which it is desired to determine whether a biomarker according to one example of the present application is methylated, and may include at least one CpG sequence. The size of the target methylation site is 5 to 150 bp, 5 to 140 bp, 5 to 130 bp, 5 to 120 bp, 5 to 110 bp, 5 to 100 bp, 5 to 90 bp, 5 to 80 bp, 5 to 70 bp, 5 to 60 bp, 5 to 50 bp, 5 to 40 bp, 5 to 30 bp, 5 to 20 bp, 5 to 15 bp, 5 to 10 bp, 10 to 150 bp, 10 to 140 bp, 10 to 130 bp, 10 to 120 bp, 10 to 110 bp, 10 to 100 bp, 10 to 90 bp, 10 to 80 bp, 10 to 70 bp, 10 to 60 bp, 10 to 50 bp, 10 to 40 bp, 10 to 30 bp, 10 to 20 bp, 10 to 15 bp, 20 to 150 bp, 20 to 140 bp, 20 to 130 bp, 20 to 120 bp, 20 to 110 bp, 20 to 100 bp, 20 to 90 bp, 20 to 80 bp, 20 to 70 bp, 20 to 60 bp, 20 to 50 bp, 20 to 40 bp, 20 to 30 bp, 20 to 25 bp, 30 to 150 bp, 30 to 140 bp, 30 to 130 bp, 30 to 120 bp, 30 to 110 bp, 30 to 100 bp, 30 to 90 bp, 30 to 80 bp, 30 to 70 bp, 30 to 60 bp, 30 to 50 bp, 30 to 40 bp, 30 to 35 bp, 40 to 150 bp, 40 to 140 bp, 40 to 130 bp, 40 to 120 bp, 40 to 110 bp, 40 to 100 bp, 40 to 90 bp, 40 to 80 bp,40 to 70 bp, 40 to 60 bp, 40 to 50 bp, 40 to 45 bp, 50 to 150 bp, 50 to 140 bp, 50 to 130 bp, 50 to 120 bp, 50 to 110 bp, 50 to 100 bp, 50 to 90 bp, 50 to 80 bp, 50 to 70 bp, 50 to 60 bp, 50 to 55 bp, 60 to 150 bp, 60 to 140 bp, 60 to 130 bp, 60 to 120 bp, 60 to 110 bp, 60 to 100 bp, 60 to 90 bp, 60 to 80 bp, It can be 60 to 70 bp, or 60 to 65 bp.

[0027] The target methylation site may include some or all of the CpG sites present in the biomarker according to an example of the present application, and may include, for example, a CpG site located at sequences 21810750 to 21810751 of human chromosome 12, sequences 29298115 to 29298116, 29298118 to 29298119, 29298124 to 29298125, 29298136 to 29298137, 29298142 to 29298143, or 29298184 to 29298185 of human chromosome 17, or sequences 19739407 to 19739408 of human chromosome 19.

[0028] As used herein, the term “methylation marker for risk of developing liver cancer” refers to a methylation marker that has a specific methylation level only in DNA isolated from a sample derived from a subject at risk of developing liver cancer, compared to the methylation level in DNA isolated from a sample derived from a subject not at risk of developing liver cancer. For example, the methylation marker for risk of developing liver cancer may be a marker that has a higher methylation level only in DNA isolated from a sample derived from a subject at risk of developing liver cancer, compared to the methylation level in DNA isolated from a sample derived from a subject not at risk of developing liver cancer.

[0029] The sequence represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 may be a methylation marker for the risk of developing liver cancer. Specifically, at least one CpG site included in the liver cancer marker represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 may have a high methylation level in a liver cancer-derived sample and a low methylation level in other derived samples, including a normal liver.

[0030] For example, if the methylation ratio of a biomarker according to an example of the present application in the biological sample is 5% or more, 10% or more, 20% or more, 25% or more, or 30% or more, the subject from which the biological sample was derived can be determined to have a risk of developing liver cancer. The methylation ratio may be specifically expressed as a b-value.

[0031] The agent capable of measuring the above methylation level may be a primer for amplifying the target methylation site of the biomarker according to an example of the present application.

[0032] The above primers include a forward primer and a reverse primer, and one of the forward primer and the reverse primer may include a methylated primer and a non-methylated primer.

[0033] The methylation primer comprises at least one CpG recognition site that recognizes a CpG sequence included in a predetermined length sequence including the target methylation site, and the unmethylation primer comprises at least one TpG recognition site that recognizes a TpG sequence included in a predetermined length sequence including the target methylation site, and the TpG sequence of the predetermined length sequence including the target methylation site is a converted unmethylated CpG sequence of the predetermined length sequence including the target methylation site. The above predetermined length is, for example, 5,000 bp or less, 4,500 bp or less, 4,000 bp or less, 3,500 bp or less, 3,000 bp or less, 2,500 bp or less, 2,000 bp or less, 1,500 bp or less, 1,400 bp or less, 1,300 bp or less, less than 1,300 bp, 1,200 bp or less, 1,100 bp or less, 1,000 bp or less, 900 bp or less, 800 bp or less, 700 bp or less, 650 bp or less, 620 bp or less, 611 bp or less, 610 bp or less, 600 bp or less, 550 bp or less, 500 bp or less, 450 bp or less, 400 bp or less, It may be 350 bp or less, 330 bp or less, 329 bp or less, 300 bp or less, 250 bp or less, 200 bp or less, 150 bp or less, 100 bp or less, or 500 bp or less. In this case, even if the lower limit of the predetermined length is not specified, a person skilled in the art will be able to clearly set the predetermined length in order to measure the methylation level of the target methylation site, and for example, it may be 2 bp or more, 5 bp or more, 10 bp or more, 20 bp or more, 30 bp or more, 40 bp or more, or 50 bp or more, but is not limited thereto.

[0034] The above TpG sequence may be converted from an unmethylated CpG sequence by an agent that differently modifies methylated CpG sequences and unmethylated CpG sequences. For example, the modifying agent may convert an unmethylated cytosine residue to thymine. For example, the modifying agent may be one or more selected from the group consisting of sulfurous acid, bisulfite, hydrogen sulfite, and disulfite.

[0035] When a template strand, for example, a sequence represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, is treated with an agent that modifies methylated CpG sequences and unmethylated CpG sequences differently, if the CpG cytosine of the template strand is in a methylated state, the CpG cytosine will not be converted to thymine, and if the CpG cytosine is in an unmethylated state, the CpG cytosine will be converted to thymine.

[0036] The CpG recognition site of the above methylation primer can recognize the CpG sequence of a methylated nucleic acid. For example, the CpG recognition site may include a CG sequence.

[0037] The TpG recognition site of the above unmethylated primer can recognize a TpG sequence converted by an agent that differentially modifies the CpG sequence of an unmethylated nucleic acid from a methylated nucleic acid. For example, the TpG recognition site may include a TG sequence.

[0038] The CpG recognition site and the TpG recognition site are located near the 3' end of the methylated primer and the unmethylated primer, respectively, and can specifically recognize methylated nucleic acids and unmethylated nucleic acids converted by agents that differently modify methylated nucleic acids and unmethylated nucleic acids, respectively. For example, the CpG recognition site and the TpG recognition site may be located within 40, 35, 30, 25, 20, 10, 9, 8, 7, 6, 5, 4, 3, or 2 bases from the 3' end of the methylated primer and the unmethylated primer, or at the 3' end.

[0039] Since the unmethylated primer has a lower Tm value than the methylated primer, to compensate for this, nucleotides may be added to the 5' end of the unmethylated primer, thereby designing the Tm of the methylated primer and the unmethylated primer to be similar. For example, the unmethylated primer may have a larger size than the methylated primer by additionally including nucleotides at the 5' end. For example, the unmethylated primer may additionally include 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1 nucleotide at the 5' end compared to the methylated primer. For example, the Tm difference between the methylated primer and the unmethylated primer may be 15°C or less, 14°C or less, 13°C or less, 12°C or less, 11°C or less, 10°C or less, 9°C or less, 8°C or less, 7°C or less, 6°C or less, 5°C or less, 4°C or less, 3°C or less, 2°C or less, or 1.5°C or less.

[0040] The above primers include a forward primer and a reverse primer, and when the methylated primer and the unmethylated primer are forward primers, the reverse primer is a reverse primer, and when the methylated primer and the unmethylated primer are reverse primers, the reverse primer is a forward primer. The reverse primer can bind to both methylated nucleic acids and unmethylated nucleic acids. Accordingly, the reverse primer may not include a CpG binding site, but when it is inevitable for the reverse primer to include a CpG binding site due to the structure of the nucleic acid, the 5'-terminal portion may include 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, 1 to 5, 1 to 4, 1 to 3, 1 to 2, for example, 1 CpG binding site. However, even in this case, it is preferable that the reverse primer be designed to have a Tm similar to that of the methylated primer and the unmethylated primer.

[0041] The methylated primer, the unmethylated primer, and the opposite primer may have a size comprising 15 to 40, 15 to 35, 15 to 30, 15 to 25, 18 to 40, 18 to 35, 18 to 30, 18 to 25, 20 to 40, 20 to 35, 20 to 30, or 20 to 25 bases.

[0042] The above methylated primer, the above unmethylated primer, and the above opposite primer may be capable of binding to a nucleic acid converted by an agent that differently modifies a methylated nucleic acid and an unmethylated nucleic acid, by including one or more, two or more, or three or more Non-CpG cytosines.

[0043] The Tm of the methylated primer, the unmethylated primer, and the opposite primer may be 50 to 80°C, 50 to 75°C, 50 to 70°C, 50 to 65°C, 55 to 80°C, 55 to 75°C, 55 to 70°C, 55 to 65°C, 60 to 80°C, 60 to 75°C, 60 to 70°C, or 60 to 65°C.

[0044] A composition according to an example of the present application comprises the methylated primer and the non-methylated primer in a ratio of 100:1 to 1:100, 100:1 to 1:50, 100:1 to 1:20, 100:1 to 1:10, 100:1 to 1:5, 100:1 to 1:1, 100:1 to less than 1:1, 100:1 to 1.3:1, 100:1 to 1.5:1, 100:1 to 2:1, 100:1 to 2.5:1, 100:1 to 3:1, 100:1 to 3.5:1, 100:1 to 4:1, 50:1 to 1:100, 50:1 to 1:50, 50:1 to 1:20, 50:1 to 1:10, 50:1 to 1:5, 50:1 to 1:1, 50:1 to less than 1:1, 50:1 to 1.3:1, 50:1 to 1.5:1, 50:1 to 2:1, 50:1 to 2.5:1, 50:1 to 3:1, 50:1 to 3.5:1, 50:1 to 4:1, 10:1 to 1:100, 10:1 to 1:50, 10:1 to 1:20, 10:1 to 1:10, 10:1 to 1:5, 10:1 to 1:1, 10:1 to less than 1:1, 10:1 to 1.3:1, 10:1 to 1.5:1, 10:1 to 2:1, 10:1 to 2.5:1, 10:1 to 3:1, 10:1 to 3.5:1, 10:1 to 4:1, 5:1 to 1:100, 5:1 to 1:50, 5:1 to 1:20, 5:1 to 1:10, 5:1 to 1:5, 5:1 to 1:1, 5:1 to less than 1:1, 5:1 to 1.3:1, 5:1 to 1.5:1, 5:1 to 2:1, 5:1 to 2.5:1, 5:1 to 3:1, 5:1 to 3.5:1, 5:1 to 4:1, 4.5:1 to 1:100, 4.5:1 to 1:50, 4.5:1 to 1:20, 4.5:1 to 1:10, 4.5:1 to 1:5, 4.5:1 to 1:1, 4.5:1 to less than 1:1, 4.5:1 to 1.3:1, 4.5:1 to 1.5:1, 4.5:1 to 2:1, 4.It may be included in a concentration ratio of 5:1 to 2.5:1, 4.5:1 to 3:1, 4.5:1 to 3.5:1, or 4.5:1 to 4:1.

[0045] For example, the concentration of the unmethylated primer may be 100% or less, less than 100%, 99.99% or less, 99.95% or less, 99.9% or less, 99.5% or less, 99% or less, 98% or less, 97% or less, 96% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 40% or less, 30% or less, or 25% or less of the concentration of the methylated primer, and may be, for example, 50% or less.

[0046] Another example of the present application relates to a kit for predicting the risk of developing liver cancer, comprising a composition for predicting the risk of developing liver cancer according to an example of the present application.

[0047] Another example of the present application relates to a method for predicting the risk of developing liver cancer, or a method for providing information for predicting the risk of developing liver cancer, comprising the step of measuring the methylation level of at least one CpG site included in a sequence region 21810279 to 21810792 of human chromosome 12, a sequence region 29298021 to 29298631 of human chromosome 17, or a sequence region 19738547 to 19739846 of human chromosome 19 in a biological sample isolated from a subject.

[0048] Specifically, a method according to an example of the present application may further include a step of measuring a methylation level of at least one CpG site included in a sequence region 21810279 to 21810792 of human chromosome 12 in a biological sample, a step of measuring a methylation level of at least one CpG site included in a sequence region 29298021 to 29298631 of human chromosome 17 in the biological sample, and / or a step of measuring a methylation level of at least one CpG site included in a sequence region 19738547 to 19739846 of human chromosome 19 in the biological sample.

[0049] The step of measuring the methylation level may be performed by a method selected from the group consisting of PCR, methylation specific PCR, real time methylation specific PCR, MethyLight PCR, MehtyLight digital PCR, EpiTYPER, PCR using methylated DNA specific binding protein, quantitative PCR, MS-HRM (Methylation sensitive high resolution melting), DNA chip, molecular beacon, next generation sequencing (NGS) panel, pyrosequencing, and bisulfite sequencing. For example, the step of measuring the methylation level may be performed using a PCR and / or MS-HRM analysis method using a methylation primer and a non-methylation primer in combination established in the present application.

[0050] For example, the methylation level can be identified by a microarray, which can utilize a probe immobilized on a solid surface. The probe can comprise a sequence complementary to a sequence of 10 to 100 contiguous nucleotides comprising the CpG site.

[0051] A method according to an example of the present application may further include a step of quantifying the degree of methylation. The quantifying step may quantify the degree of methylation of a biomarker included in the biological sample by comparing the AUMC (Area under the melting curve) of melting curves of the biological sample, a sample in which the biomarker according to an example of the present application is 100% methylated, and a sample in which the biomarker according to an example of the present application is 100% unmethylated. The melting curve may be normalized.

[0052] Specifically, the quantifying step may include: obtaining a melt curve of the biological sample; obtaining a normalized melt curve of the biological sample in which the content ratio of methylated nucleic acids and unmethylated nucleic acids is known; and comparing the melt curve of the biological sample and the normalized melt curve to quantify the degree of methylation of the biological sample. The melt curve of the biological sample may be obtained through HRM analysis. For example, the nucleic acid may be a nucleic acid comprising at least one CpG site included in a nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, and having a continuous partial sequence of the nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. As an example, the nucleic acid may be a nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. The melt curve of the biological sample may be normalized before being compared with the normalized melt curve.

[0053] A method according to an example of the present application may further include, after the step of measuring the methylation level, a step of comparing the methylation level with the methylation level of a control group. The control group refers to DNA isolated from a biological sample whose tissue of origin is already known, and any sample derived from a subject without liver cancer or a subject with liver cancer may be used. For example, when a sample derived from a subject with liver cancer is used as the control group, if the methylation level of the DNA isolated from the biological sample is similar to the methylation level of the DNA isolated from the control group, the subject from which the biological sample was derived may be determined to have a risk of developing liver cancer. In addition, when a sample derived from a subject without liver cancer is used as the control group, if the methylation level of the DNA isolated from the biological sample is higher than the methylation level of the control group, the subject from which the biological sample was derived may be determined to have a risk of developing liver cancer. The subject may be, for example, a vertebrate, mammal, rodent, goat, deer, pig, bird, chicken, turkey, cow, horse, sheep, fish, or primate, for example, a human.

[0054] A method according to an example of the present application may further include a step of measuring the concentration of alpha fetoprotein (AFP) in the biological sample, and / or a step of collecting information on the sex and / or age of the subject.

[0055] The composition and method according to an example of the present application can determine whether a biomarker is methylated with high sensitivity even when the concentration of the methylated biomarker in a biological sample is very low.

[0056] To complement the shortcomings of conventional experimental verification methods, when designing MS-HRM primers, a methylated primer containing a CpG recognition site that recognizes a CpG sequence within the primer was used, and an unmethylated primer containing a TpG recognition site that recognizes a TpG sequence to be used for amplification of the unmethylated template strand was used in combination to prevent amplification of only the methylated template strand. At this time, in order to prevent the relatively low sensitivity of MS-HRM and the biased amplification of primers containing TpG, a method was developed to increase the binding opportunity of primers containing CpG and decrease the binding opportunity of primers containing TpG by controlling the temperature of the primer annealing step of PCR.

[0057] Therefore, more sensitive PCR can be performed for targets present in very small amounts, such as circulating tumor DNA present in the blood, such as nucleic acids represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, and experiments can be designed by controlling the degree of binding of methylated and unmethylated primers to the template strand according to the purpose, depending on the annealing temperature and the concentration ratio of the primers. It can be used to design a new experimental validation method by complementing the shortcomings of existing qMSP, MethyLight, and MS-HRM analysis methods, and methylation markers represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 can be detected through liquid biopsy, and it has higher sensitivity than existing MS-HRM analysis methods and can quantify the methylation level.

[0058] Furthermore, it allows for the measurement of relative methylation ratios in the same test tube without the need for a control marker analysis, and it achieves high detection sensitivity by avoiding the use of probes that interfere with amplification efficiency. Furthermore, the amplification efficiency of methylated and unmethylated DNA can be controlled to measure very low methylation levels in biological samples such as blood.

[0059] The composition and method according to an example of the present application can measure the methylation level of a sample more sensitively than the existing PCR-based analysis method even under conditions where a trace amount of a desired target nucleic acid is present, without generating non-specific amplification products by using a mixed methylated primer and a non-methylated primer.

[0060] A composition and method according to an example of the present application can achieve high sensitivity and specificity by confirming the DNA methylation level of ctDNA (circulating tumor DNA) present in a small amount in a cancer patient among cfDNA (cell-free DNA) present in a biological sample, for example, blood, for example, the methylation level of at least one CpG site included in a nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, through a semi-quantitative method within the sample.

[0061] For example, the concentration of methylated nucleic acid in the biological sample is 100 ng / ul or less, 90 ng / ul or less, 80 ng / ul or less, 70 ng / ul or less, 60 ng / ul or less, 50 ng / ul or less, 40 ng / ul or less, 30 ng / ul or less, 20 ng / ul or less, 15 ng / ul or less, 10 ng / ul or less, 9 ng / ul or less, 8 ng / ul or less, 7 ng / ul or less, 6 ng / ul or less, 5 ng / ul or less, 4 ng / ul or less, 3 ng / ul or less, 2 ng / ul or less, 1.5 ng / ul or less, 1 ng / ul or less, 0.5 ng / ul or less, 0.4 ng / ul or less, 0.3 ng / ul or less, 0.2 ng / ul or less, 0.1 ng / ul or less, 0.05 ng / ul or less, 0.04 ng / ul or less, 0.03 ng / ul or less, 0.02 ng / ul or less, 0.01 ng / ul or less, 0.009 ng / ul or less, 0.008 ng / ul or less, 0.007 ng / ul or less, 0.006 ng / ul or less, 0.005 ng / ul or less, or 0.003 ng / ul or less. The nucleic acid may be, for example, a nucleic acid comprising at least one CpG site included in a nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, and having a continuous partial sequence of a nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. As an example, the nucleic acid may be a nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

[0062] For example, the biological sample may include methylated nucleic acids and unmethylated nucleic acids, and the concentration of the methylated nucleic acids may be less than or equal to 75%, less than or equal to 70%, less than or equal to 60%, less than or equal to 50%, less than or equal to 40%, less than or equal to 30%, less than or equal to 25%, less than or equal to 20%, less than or equal to 19%, less than or equal to 18%, less than or equal to 15%, less than or equal to 10%, less than or equal to 5%, less than or equal to 4.5%, less than or equal to 4%, less than or equal to 3.5%, less than or equal to 3%, less than or equal to 2.5%, less than or equal to 2%, less than or equal to 1.5%, less than or equal to 1.4%, less than or equal to 1.3%, less than or equal to 1.2%, less than or equal to 1.1%, less than or equal to 1%, less than or equal to 0.9%, less than or equal to 0.8%, less than or equal to 0.7%, less than or equal to 0.6%, less than or equal to 0.5%, or less than or equal to 0.45% of the concentration of the unmethylated nucleic acids. For example, the nucleic acid may be a nucleic acid comprising at least one CpG site included in a nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, and having a contiguous portion of the sequence of the nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. As an example, the nucleic acid may be a nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

[0063] For example, the biological sample includes methylated nucleic acids and unmethylated nucleic acids, and based on 100% of the total strands of the methylated nucleic acids and the unmethylated nucleic acids, the methylated nucleic acids are 100% or less, less than 100%, 99% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, less than 10%, 5% or less, less than 5%, 4.5% or less, 4% or less, 3.5% or less, 3% or less, 2.5% or less, 2% or less, 1.5% or less, 1.4% or less, It may contain 1.3% or less, 1.2% or less, 1.1% or less, 1% or less, 0.9% or less, 0.8% or less, 0.7% or less, 0.6% or less, 0.5% or less, or 0.4% or less. For example, the nucleic acid may be a nucleic acid comprising at least one CpG site included in a nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, and having a contiguous portion of the sequence of the nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. As an example, the nucleic acid may be a nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

[0064] For example, the biological sample may contain methylated nucleic acids of 20,000 strands or less, 15,000 strands or less, 10,000 strands or less, 5,000 strands or less, 4,000 strands or less, 3,000 strands or less, 2,000 strands or less, 1,000 strands or less, 500 strands or less, 400 strands or less, 300 strands or less, 200 strands or less, 150 strands or less, 100 strands or less, 90 strands or less, 80 strands or less, 70 strands or less, 60 strands or less, 50 strands or less, 40 strands or less, 30 strands or less, 20 strands or less, 10 strands or less, 9 strands or less, 8 strands or less, 7 strands or less, 6 strands or less, 5 strands or less, 4 strands or less, It may include 3 or fewer strands, 2 or fewer strands, or 1 or fewer strands. For example, the nucleic acid may be a nucleic acid that includes at least one CpG site included in a nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, and has a continuous partial sequence of a nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. As an example, the nucleic acid may be a nucleic acid represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

[0065] In one example of the present application, the biological sample may include at least one selected from the group consisting of blood, plasma, serum, platelets, tissue, cells, feces, and urine.

[0066] In one example of the present application, the liver cancer may be hepatocellular carcinoma.

[0067] A method according to one embodiment of the present application may further comprise a step of treating the subject. The step of treating may include administering an effective amount of a therapeutic agent to the subject, performing chemotherapy, hormone therapy, radiation therapy, surgery, or a combination thereof. The therapeutic agent may be, for example, a liver cancer treatment agent.

[0068] The above treatments include, for example, Afatinib, AK105, Anlotinib, Apatinib, Atezolizumab, Avelumab, Axitinib, Bevacizumab, Bosutinib, BSC, Cabozantinib, Cabozantinib-S-Malate, Camrelizumab, Camertinib, Carboplatin, Capecitabine, Celecoxib, CC-122, CF102, Crizotinib, Dasatinib, Docetaxel, Donafenib, Dovitinib (Dovitinib), doxorubicin, durvalumab, EKB-569, entrectinib, epirubicin, erlotinib, etoposide, everolmus, FGF401, FOLFOX 4, fostamatinib, galunisertib, gefitinib, gemcitabine, IBI305, ibrutinib, imatinib, INC280, infigratinib, ipilimumab, irinotecan, lapatinib, leflunomide, lenvatinib (Lenvatinib), LY2875358, Mesylate, Mitomycin c, MSC2156119J, Neratinib, Nilotinib, Nintedanib,Nivolumab, oxaliplatin, palbociclib, panobinostat, pazopanib, PDR001, pembrolizumab, pemigatinib, Pexavec, phosphate, ramucirumab, regorafenib, ruxolitinib, semaxinib, selumetinib, SGO-110, SHR-1210, sintilimab, sorafenib, SU6656, sunitinib, sintilimab, spartalizumab It may include sutent, TACE, Tasquinimod, Temozolomide, Temsirolimus, Tislelizumab, Tivantinib, Tosylate, toripalimab, Tremelimumab, vandetanib, vatalanib, XL888, Y90, a pharmaceutically acceptable salt thereof, or a combination thereof.

[0069] Another example of the present application relates to a method for treating liver cancer, comprising treating a subject identified as having a risk of liver cancer according to an example of the present application. The step of treating the subject is as described above.

[0070] A biomarker according to an example of the present application can achieve higher sensitivity than the existing liquid biopsy diagnostic method through diagnosis using liquid biopsy, thereby significantly increasing the efficiency of liver cancer screening and significantly increasing the survival rate of liver cancer patients.

[0071] Furthermore, one example of the present application can provide a biomarker capable of early diagnosis of liver cancer using a blood-based liquid biopsy, and a molecular testing method utilizing the same. Specifically, the presence or absence of cfDNA derived from liver cancer cells in a sample can be detected by assessing the DNA methylation level of blood-derived cell-free DNA (cfDNA).

[0072] FIG. 1 is a drawing confirming the methylation level of markers in each tissue according to an example of the present application, in which the horizontal axis indicates CGRC_N: Cancer Genome Research Center normal; LIHC_N: Liver Hepatocellular carcinoma normal, CGRC_T: Cancer Genome Research Center tumor, and LIHC_T: Liver Hepatocellular carcinoma tumor.

[0073] FIG. 2 is a diagram showing the methylation distribution of markers according to an example of the present application in normal liver and liver disease, where Liver_N on the horizontal axis means: normal liver; NAFLD: non-alcoholic fatty liver disease; NASH: non-alcoholic steatohepatitis; LGDN: low-grade dysplastic nodule; HGDN: high-grade dysplastic nodule; HCC: hepatocellular carcinoma; HepG2: hepatocellular carcinoma (HCC) cell line.

[0074] Figures 3a to 3c are diagrams showing the results of verifying the performance of a biomarker according to an example of the present application using general methylation data as an independent cohort.

[0075] FIG. 4 is a diagram showing the liver cancer specificity of a biomarker according to an example of the present application, in which the X-axis represents normal and cancer tissue samples of 23 cancer types data sets including liver cancer, the Y-axis represents the biomarker, and the color of the matrix represents the methylation level.

[0076] FIGS. 5a to 5c show the results of confirming the possibility of distinguishing between methylated and unmethylated strands by a method for measuring the methylation level of a biomarker according to an example of the present application, using Control DNA (EpiTect PCR Control DNA Set, Qiagen, 59695), gDNA of a liver cancer cell line, and sulfite-converted gDNA derived from human Buffy Coat.

[0077] FIGS. 6A to 6C are results of analyzing the limit of detection for methylated and unmethylated DNA strands of marker 1, a biomarker according to an example of the present application, using a methylation level measurement method according to an example of the present application.

[0078] Figure 7 is a boxplot showing the methylation levels of biomarkers according to an example of the present application for normal and tumor tissue samples of various cancer types.

[0079] Figures 8a to 8c are diagrams showing the results of MS-HRM analysis based on sulfite-converted gDNA derived from Buffy Coat collected from 55 healthy individuals. Figures 8a and 8b are diagrams showing normalized melting point curves of all samples, and Figure 8c is a boxplot showing the distribution of the integral value (AUMC) of each sample based on the melting point curve.

[0080] Figure 9a is a boxplot showing the AUMC of 81 healthy people and 319 HCC patients, and the AUMC value of 81 healthy people is 97 th The cut-off set based on percentile is indicated by a dotted line.

[0081] Figure 9b shows the results of analyzing the accuracy of liver cancer diagnosis by Marker 1, a biomarker according to an example of the present application, for a total of 420 clinical samples.

[0082] FIG. 10 is a diagram showing the results of increasing liver cancer diagnosis accuracy when marker 1, a biomarker according to an example of the present application, is combined with various biomarkers.

[0083] Figure 11 is a drawing confirming the liver cancer specificity of a diagnostic marker according to an example of the present application.

[0084] FIG. 12 is a diagram confirming that the risk of liver cancer is accurately predicted through the methylation level of a diagnostic marker according to an example of the present application.

[0085] Hereinafter, the present application will be described in more detail with reference to the following examples. However, these examples are merely intended to illustrate the present application, and the scope of the present application is not limited by these examples.

[0086]

[0087] Example 1. Discovery of markers for predicting the risk of liver cancer.

[0088] To identify markers predicting the risk of developing liver cancer that can be detected by blood biopsy, we analyzed DNA methylation data from The Cancer Genome Atlas (TCGA) database and the Cancer Genome Research Center (CGRC). Methylation data from normal and liver cancer tissues in these databases were analyzed to identify CpG sites that were hypomethylated (<15%) in over 95% of normal liver samples, hypomethylated (<15%) in over 95% of blood samples, and hypermethylated (>30%) in liver cancer samples.

[0089] To discover universal biomarkers, machine learning was performed on each data set in the above database to find CpG sites with high machine learning importance rankings.

[0090] To identify markers that could be detected by blood biopsy, we additionally identified a group of marker candidates that were hypomethylated to less than 15% in normal tissues of organs other than the liver.

[0091] Information on markers selected to satisfy all of the above conditions is shown in Table 1. The selected biomarker is referred to as “marker 1” in this specification.

[0092] In addition, two markers that were found to be specific for liver cancer were additionally selected and named “marker 2” and “marker 3,” respectively, and their information is shown in Table 1.

[0093]

[0094] In the examples that follow, as an example of marker 1, a CpG site located at sequences 21810750 to 21810751 of chromosome 12 was used as a representative experiment, as an example of marker 2, a CpG site located at sequences 29298124 to 29298125 of chromosome 17 was used as a representative experiment, and as an example of marker 3, a CpG site located at sequences 19739407 to 19739408 of chromosome 19 was used as a representative experiment. In the sequence of Table 1, the CpG sites located at sequences 21810750 to 21810751 of chromosome 12, the CpG sites located at sequences 29298124 to 29298125 of chromosome 17, and the CpG sites located at sequences 19739407 to 19739408 of chromosome 19 are indicated in bold and underlined.

[0095] The selected liver cancer markers were visualized as a box plot using the Graph pad prism tool and are shown in Figure 1 (X-axis: sample type; CGRC_N: Cancer Genome Research Center normal; LIHC_N: Liver Hepatocellular carcinoma normal; CGRC_T: Cancer Genome Research Center tumor; LIHC_T: Liver Hepatocellular carcinoma tumor; Y-axis: methylation B-value).

[0096] As shown in Fig. 1, a marker according to an example of the present application is hypomethylated in normal blood, normal liver tissue, normal tissue of organs other than the liver, and cancerous tissue of organs other than the liver, and exhibits a characteristic of being specifically hypermethylated in liver cancer samples. Specifically, a marker according to an example of the present application exhibits an average methylation value of 30% or more in liver cancer samples, but a significantly lower methylation level in other samples, so that liver cancer samples can be specifically distinguished through the methylation level of the marker.

[0097]

[0098] Example 2. Methylation mutations according to liver cancer development stage

[0099] In order to identify methylation variations according to the stage of liver cancer development for a biomarker according to an example of the present application, data sets according to the stage of cancer development were downloaded from the GEO (Gene Expression Omnibus) database. Multiple methylation data at each stage were combined and visualized as a box plot using the Graph pad prism tool, which is shown in Fig. 2 (X-axis: sample type; Liver_N: normal liver; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; LGDN: low-grade dysplastic nodule; HGDN: high-grade dysplastic nodule; HCC: Hepatocellular carcinoma; HepG2: Hepatocellular carcinoma (HCC) cell line; Y-axis: methylation B-value).

[0100] As shown in Fig. 2, a biomarker according to an example of the present application shows hypomethylation in normal blood, normal liver tissue, fatty liver, and cirrhosis, and methylation gradually increases from the dysplastic liver and dysplastic nodule stage, which is a precancerous lesion of liver cancer, to show a significantly high methylation level in hepatocellular carcinoma (HCC). In Fig. 2, the X-axis represents a sample, and the Y-axis represents a methylation value.

[0101]

[0102] Example 3. Validation of the clinical performance of biomarkers in an independent cohort.

[0103] To validate the biomarker according to an example of the present application in several independent cohorts, four liver cancer methylation data sets (GSE54503, GSE56588, GSE60753, and GSE89852) were downloaded from the GEO (Gene Expression Omnibus) database and used in the experiment. The two data sets (CGRC HCC, TCGA HCC) used for marker discovery in Example 1 and the above four data sets were combined, and hierarchical clustering was performed using the biomarker according to an example of the present application, and the results were visualized and shown in FIGS. 3A to 3C (X-axis: sample, Y-axis: Probe ID of marker, green box: normal sample, red box: cancer sample).

[0104] FIG. 3a shows the clustering result of a single marker, Marker 1, according to an example of the present application, FIG. 3b shows the clustering result of a combination marker, Marker 1 and Marker 2, and FIG. 3c shows the clustering result of a combination marker, Marker 1 and Marker 3. In FIGS. 3a to 3c, the color of the heatmap indicates the degree of methylation, with a range from white to red indicating higher methylation. As shown in FIGS. 3a to 3b, when all samples of the six data sets were clustered using the heatmap, it was confirmed that the normal samples, indicated in green, and the liver cancer samples, indicated in pink, were distinguished. In addition, when Marker 1, Marker 2, or Marker 3 according to an example of the present application were applied together to perform hierarchical clustering, the tumor coverage was further improved.

[0105]

[0106] Example 4. Confirmation of the specificity of biomarkers for liver cancer.

[0107] In order to confirm the liver cancer specificity of the biomarker according to an example of the present application, the average methylation degree was analyzed by cancer type using the methylation data of the TCGA and GEO databases used in Example 1 or Example 2.

[0108] Specifically, the methylation levels of marker 1 and marker 2 for each data set were confirmed as a heatmap using the ggplot2 R package in R software, and are shown in Figure 4 (blue: hypomethylation, red: hypermethylation, X-axis: sample, Y-axis: Probe ID of marker, green box: normal sample, red box: cancer sample).

[0109] As shown in Fig. 4, the average methylation values ​​of biomarkers according to an example of the present application were confirmed in each cancer type. Marker 1 and Marker 2 appeared in red only in liver cancer samples, confirming hypermethylation, and in blue in normal liver and other cancer types, confirming a hypomethylated pattern. Therefore, both biomarkers showed high methylation levels only in liver cancer and low methylation levels in other cancer types, confirming liver cancer specificity.

[0110]

[0111] Example 5. Establishment of a method for measuring the methylation level of a biomarker.

[0112] A method for measuring the methylation level of a biomarker according to an example of the present application was established as follows.

[0113] Various samples and control samples including marker 1 according to an example of the present application were prepared as shown in Table 2 and used in the experiment. Samples No. 2, 3, and 5 were purchased from Qiagen and used. Sample No. 3 was obtained by treating the gDNA of sample No. 2 with sulfur dioxide using EpiTect Bisulfite Kit so that all cytosine residues were converted to thymine. Sample No. 5 was obtained by 100% methylating the gDNA of sample No. 2 with SssⅠ methylase and then treating it with sulfur dioxide using EpiTect Bisulfite Kit so that cytosines other than CpG cytosine were converted to thymine. For sample No. 4, gDNA was extracted from peripheral blood mononuclear cells using a buffy coat isolated from the blood of a healthy person using QIAmp DNA Blood Kit (Qiagen, Cat. No. 51104) according to the manufacturer's instructions. The extracted gDNA was then converted to sulfur dioxide using EZ DNA Methylation-Lightning Kit and used in the experiment. For sample number 6, gDNA from the hepatoma cell line Huh-1 was prepared for the experiment using the QIAmp DNA Blood Kit and EZ DNA Methylation-Lightning Kit, in the same manner as PBMCs. Each sample was diluted to 0.33 ng / μL after measuring its concentration using Qubit.

[0114] Sample number Sample name Sample description Methylation status graph color 5 1 NTC non-template control - black 2 EpiTect gDNA non-sulfite treated sample - green 3 EpiTect Unmet. DNA 100% unmethylated sample X purple 4 Buffy Coat gDNA normal blood cell derived sample X orange 5 EpiTect Met. DNA 100% methylated sample O blue 6 Huh-1 gDNA liver cancer cell derived sample O red

[0115] The sulfite-converted sequences of biomarkers according to an example of the present application are shown in Table 3. In Table 3, C, where CT conversion occurred by sulfurous acid treatment, is indicated by a lowercase t, and methylated CpG sites are indicated by a capital letter CG. In Table 3, CpG sites representatively used in experiments in the examples of the present application are indicated in bold and underlined.

[0116]

[0117] * t: C where CT conversion occurred by sulfurous acid treatment

[0118] * CG: Methylated CG

[0119]

[0120] The size of the PCR amplification product was set to be 50 to 100 bp, and considering that the PCR annealing temperature was approximately 60°C, the T of the primers m was set to 60 to 65℃. A CpG or TpG sequence was included near the 3'-end of either the forward or reverse primer so that it could specifically bind to either the methylated or unmethylated strand. Since the methylated template strand remains without the CpG cytosine being converted to thymine after sulfurous acid treatment, the methylated primer was designed to include CpG as it is, and the unmethylated primer was designed to include TpG. At this time, since the Tm of the primer that specifically binds to the unmethylated template strand is lower than that of the primer that specifically binds to the methylated template strand, the Tm of the two types of primers can be designed to be similar by adding nucleotides to the 5'-end to compensate for this. The primer in the opposite direction to the methylated primer and the unmethylated primer was designed to be a primer that can bind regardless of the methylation status of the methylated strand and the unmethylated strand. All primers were designed to specifically bind to the sulfite-converted DNA strand by including at least two non-CpG cytosines. Exemplary sequences of primer sets prepared for Marker 1, a biomarker according to an example of the present application, are shown in Table 4. In each primer sequence, the portions corresponding to CpG or non-CpG cytosines of Marker 1 are indicated in capital letters, and the other bases are indicated in lowercase letters.

[0121] nameSeq (5'->3')SEQ ID NO.Methylated Forward Primer for marker 1aAcCGACGcCGAaAAaAaCG7Methylated Reverse Primer for marker 1gaaggTtTtggagaTTtTtgtaaTag8Unmethylated Forward Primer for marker 1ttAcaAaAcCAACAcCAAaAAaAaCA9

[0122] Using the primers in Table 4, the PCR Mixture was prepared as follows (based on 1 rxn):

[0123] Master Mix (2X): 12.5 μL (Final Conc. 1X)

[0124] EvaGreen (20X): 1.25 μL (Final Conc. 1X)

[0125] Methylated Forward Primer (10 uM): 1 μL (Final Conc. 0.4 uM)

[0126] Methylated Reverse Primer (10 uM): 1 μL (Final Conc. 0.4 uM)

[0127] Unmethylated Forward Primer (10 uM): 0.5 μL (Final Conc. 0.2 uM)

[0128] NFW (nuclease-free water): 5.75 μL

[0129] Total: 22 μL

[0130] After dispensing 22 μL of the prepared PCR mixture into each well of a 96-well plate, 3 μL of a control nucleic acid sample at a concentration of 0.33 ng / μL was dispensed into each well. PCR reaction and HRM analysis were performed under the following conditions:

[0131] 95℃ 5 minutes / 95℃ 20 seconds - 69℃ 40 seconds (20 cycles, starting at 69℃ and decreasing by 0.3℃ per cycle to end at 63℃): PCR reaction

[0132] 95℃ 20 seconds - 63℃ 40 seconds (40 cycles, constant at 63℃): PCR reaction

[0133] 63℃ 5 minutes / 60℃ - 95℃ (increase by 0.2℃ and measure fluorescence value after 10 seconds of reaction): HRM analysis

[0134] Fluorescence values ​​for PCR and HRM analyses were confirmed, and melting curves or peaks were observed to identify the characteristics of methylated and unmethylated controls. The PCR and HRM analysis results for Marker 1 according to an example of the present application are shown in Figures 5a to 5c.

[0135] Figure 5a is a diagram observing the fluorescence signal at the PCR stage during the MS-HRM analysis process. During the MS-HRM analysis, only signals for samples converted to methylsulfite were confirmed. Specifically, the primers for the biomarker according to an example of the present application, as measured by the NTC and EpiTect gDNA results, did not form dimers through primer-to-primer reaction, did not react with gDNA that was not converted to methylsulfite, and did not produce PCR amplification products. Therefore, it was confirmed that the designed primers specifically reacted only with samples converted to methylsulfite.

[0136] Fig. 5b is a melt curve showing the decomposition of the double strand of the PCR amplification product according to the increase in temperature after the PCR reaction, and Fig. 5c is a melt peak graph showing -(differential value) for the melt curve of Fig. 5b. In the case of the methylated template strand, CpG was maintained as is, and denaturation of the PCR amplification product occurred at a relatively higher temperature than that of the unmethylated template strand modified with TpG. In other words, it can be confirmed that the double strand of the PCR amplification product generated by unmethylated DNA is decomposed into single strands at a lower temperature than that of the PCR amplification product generated by methylated DNA. Therefore, it can be seen that the primer designed to target the biomarker according to an example of the present application can reflect the characteristics of the amplification product according to the methylation level of the sample.

[0137]

[0138] Example 6. Limit of detection (LoD)

[0139] (1) Minimum detection limit analysis (1)

[0140] Control nucleic acid samples (Buffy Coat and Huh-1 sulfite-converted gDNA) to be used were diluted to 1 ng / μL after measuring the concentration using Qubit. The 1 ng / μL control nucleic acid was serially diluted 2-fold with water to prepare each sample up to a concentration of 0.016 ng / μL (1 ng / μL, 0.5 ng / μL, 0.25 ng / μL, 0.13 ng / μL, 0.06 ng / μL, 0.03 ng / μL, and 0.016 ng / μL, a total of 7 concentrations of control nucleic acid).

[0141] Using the primers in Table 4, the PCR Mixture was prepared as follows (based on 1 rxn):

[0142] Master Mix (2X): 12.5 μL (Final Conc. 1X)

[0143] EvaGreen (20X): 1.25 μL (Final Conc. 1X)

[0144] Methylated Forward Primer (10 uM): 1 μL (Final Conc. 0.4 uM)

[0145] Methylated Reverse Primer (10 uM): 1 μL (Final Conc. 0.4 uM)

[0146] Unmethylated Forward Primer (10 uM): 0.5 μL (Final Conc. 0.2 uM)

[0147] NFW (nuclease-free water): 5.75 μL

[0148] Total: 22 μL

[0149] After dispensing 22 μL of the prepared PCR mixture into each well of a 96-well plate, 3 μL of a control nucleic acid sample at a concentration of 0.33 ng / μL was dispensed into each well. PCR reaction and HRM analysis were performed under the following conditions:

[0150] 95℃ 5 minutes / 95℃ 20 seconds - 69℃ 40 seconds (20 cycles, starting at 69℃ and decreasing by 0.3℃ per cycle to end at 63℃): PCR reaction

[0151] 95℃ 20 seconds - 63℃ 40 seconds (40 cycles, constant at 63℃): PCR reaction

[0152] 63℃ 5 minutes / 60℃ - 95℃ (increase by 0.2℃ and measure fluorescence value after 10 seconds of reaction): HRM analysis

[0153] The correlation between PCR Cq values ​​and input concentrations was confirmed, and the limit of detection (LoD) was verified. The area under the melting curve (AUMC) based on the normalized melting point curve across all concentration ranges was used to confirm whether PCR amplification products of methylated and unmethylated template strands were formed correctly.

[0154] As shown in Fig. 6a, it was confirmed that the Cq value decreased as the concentration increased in the methylated (Huh-1 gDNA) and unmethylated (Buffy Coat gDNA) gDNA converted to sulfur dioxide, respectively, and it was confirmed that the correlation of PCR amplification according to the concentration was statistically significant (the higher the concentration of the sample used, the faster the PCR amplification, so the lower the Cq value was confirmed). Theoretically, the number of strands in 1 ng DNA is 304 strands, and since 0.0625 ng, the lowest amount of DNA used in the above experiment, has 19 strands, it indicates that up to 19 strands can be stably detected.

[0155] As shown in Fig. 6b, the AUMC (area under the melting curve) value was calculated based on the normalized melting point curve of the PCR amplification product of the used sample, and it was confirmed that the AUMC corresponding to each methylation feature appeared similarly in the concentration ranges of all methylated and unmethylated gDNA.

[0156]

[0157] (2) Minimum detection limit analysis (2)

[0158] Human Methylated & Non-methylated DNA Set (Cat. # D5014) from Zymo Research was converted to methylsulfoxide using the same company's EZ DNA Methylation-Lightning™ Kit (Cat. # D5030), and then quantified using the Qubit™ ssDNA Assay Kit (Cat. # Q10212). After that, the converted methylated & non-methylated DNA were diluted to 0.1 ng / uL with Nuclease-free Water (Cat. # AM9937), and serial dilutions were performed 4-fold by diluting the methylated DNA with the non-methylated DNA to prepare samples with methylated DNA levels of 100%, 25%, 6.25%, 1.56%, 0.39%, and 0%.

[0159] An exemplary sequence of a primer set prepared for Marker 1, a biomarker according to an example of the present application, is shown in Table 5. In each primer sequence, the site corresponding to CpG or non-CpG cytosine of Marker 1 is written in capital letters, and the other bases are written in lowercase letters.

[0160] nameSeq (5'->3')SEQ ID NO.Methylated Forward Primer for marker 1gagaaggTtTtggagaTTtTtgtaaTag10Methylated Reverse Primer for marker 1ctccttAcaAaAcCGACGcCG11Unmethylated Reverse Primer for marker 1tccttAcaAaAcCAACAcCA12

[0161] The PCR mixture used in the limit of detection (LoD) experiment was prepared as follows using the primers in Table 5 (based on 1 rxn):

[0162] Master Mix (2X): 12.5 μL (Final Conc. 1X)

[0163] LightCycler (20X): 1.25 μL (Final Conc. 1X)

[0164] Primer Mixture (concentration of each primer is 12 μM): 1.25 μL (Final Conc. 0.6 μM)

[0165] Total: 15 μL

[0166] After dispensing 15 μL of the prepared PCR mixture into each well of a 96-well plate, 10 μL of methylated DNA samples (100%, 25%, 6.25%, 1.56%, 0.39%, and 0%) at concentrations of 0.1 ng / μL were dispensed into each well. PCR reaction and HRM analysis were performed under the following conditions:

[0167] 95℃ 5 minutes / 95℃ 10 seconds - 63℃ 30 seconds - 72℃ 15 seconds (39 Cycles): PCR reaction

[0168] 72℃ 5 minutes / 60℃ - 95℃ (increase by 0.2℃ and measure fluorescence value after 10 seconds of reaction): HRM analysis

[0169] The Temperature-shifted Area under the Melting Curve (TS-AUMC) was determined according to the ratio of methylated DNA used, and the limit of detection (LoD), which measures detectable methylated DNA when non-methylated DNA exists as a background, was determined.

[0170] As shown in Fig. 6c, even in an environment where 99.6% of unmethylated strands exist, the resolution of the 0% and the Temperature-shifted AUMC value, which is the Methylation Signal value, was confirmed. Specifically, when the level of 0.4% in 1 ng of input DNA is converted to a copy number, it is calculated as a level of 1.2 copies of the target strand, so the method for measuring the methylation level of the biomarker established in Example 5 showed the effect of being able to detect a trace amount of methylated strands even when a large amount of unmethylated strands exist in the blood.

[0171]

[0172] Example 7. Diagnosis of liver cancer using tissue samples

[0173] gDNA was extracted and converted to sulfite from normal and tumor tissues collected from patients with liver cancer (LIHC) (normal; 120, tumor; 115), lung cancer (LUAD) (normal; 8, tumor; 9), colorectal cancer (COAD) (normal; 10, tumor; 10), kidney cancer (KIRP and KIRC) (normal; 16, tumor; 15), bladder cancer (BLCA) (normal; 10, tumor; 9), and thyroid cancer (THYM) (normal; 6, tumor; 6). Kidney cancer was classified as kidney renal papillary cell carcinoma (KIRP) (normal; 9, tumor; 5) or kidney renal clear cell carcinoma (KIRC) (normal; 7, tumor; 10).

[0174] Specifically, the PCR Mixture was prepared as follows using the primers in Table 4 (based on 1 rxn):

[0175] Master Mix (2X): 12.5 μL (Final Conc. 1X)

[0176] EvaGreen (20X): 1.25 μL (Final Conc. 1X)

[0177] Methylated Forward Primer (10 uM): 1 μL (Final Conc. 0.4 uM)

[0178] Methylated Reverse Primer (10 uM): 1 μL (Final Conc. 0.4 uM)

[0179] Unmethylated Forward Primer (10 uM): 0.5 μL (Final Conc. 0.2 uM)

[0180] NFW (nuclease-free water): 5.75 μL

[0181] Total: 22 μL

[0182] The prepared sample was quantified, diluted to 0.33 ng / μL, and 3 μL of the sample was added. PCR reaction and HRM analysis were performed under the following conditions:

[0183] 95℃ 5 minutes / 95℃ 20 seconds - 69℃ 40 seconds (20 cycles, starting at 69℃ and decreasing by 0.3℃ per cycle to end at 63℃): PCR reaction

[0184] 95℃ 20 seconds - 63℃ 40 seconds (40 cycles, constant at 63℃): PCR reaction

[0185] 63℃ 5 minutes / 60℃ - 95℃ (increase by 0.2℃ and measure fluorescence value after 10 seconds of reaction): HRM analysis

[0186] The MS-HRM analysis method established in Example 5 was applied to each sample, and the Area Under the Melting Curve (AUMC) was derived from the normalized melting point curve.

[0187] As shown in Fig. 7, a biomarker according to an example of the present application showed a significantly high methylation level in liver cancer tissue, and thus can be utilized for liver cancer diagnosis.

[0188]

[0189] Example 8. Analysis of blood samples from healthy individuals

[0190] For sample preparation, gDNA was extracted and converted to bisulfite from Buffy Coat samples collected from 55 healthy individuals. To measure the methylation level of Marker 1 according to an example of the present application, a PCR mixture was prepared using the primers in Table 4 as follows (based on 1 rxn):

[0191] Master Mix (2X): 12.5 μL (Final Conc. 1X)

[0192] EvaGreen (20X): 1.25 μL (Final Conc. 1X)

[0193] Methylated Forward Primer (10 uM): 1 μL (Final Conc. 0.4 uM)

[0194] Methylated Reverse Primer (10 uM): 1 μL (Final Conc. 0.4 uM)

[0195] Unmethylated Forward Primer (10 uM): 0.5 μL (Final Conc. 0.2 uM)

[0196] NFW (nuclease-free water): 5.75 μL

[0197] Total: 22 μL

[0198] 3 μL of Buffy Coat sample (concentration 0.33 ng / μL) and 3 μL of EpiTect Unmethylated DNA and Methylated DNA were added to each well containing the PCR mixture. PCR reaction and HRM analysis were performed under the following conditions:

[0199] 95℃ 5 minutes / 95℃ 20 seconds - 69℃ 40 seconds (20 cycles, starting at 69℃ and decreasing by 0.3℃ per cycle to end at 63℃): PCR reaction

[0200] 95℃ 20 seconds - 63℃ 40 seconds (40 cycles, constant at 63℃): PCR reaction

[0201] 63℃ 5 minutes / 60℃ - 95℃ (increase by 0.2℃ and measure fluorescence value after 10 seconds of reaction): HRM analysis

[0202] The MS-HRM analysis method established in Example 5 was applied to each sample, and a normalized melting point curve and a melting point peak (Peak) and AUMC, which were differentiated with respect to temperature and took negative values, were derived.

[0203] As shown in Fig. 8, all Buffy Coat gDNAs from 55 healthy individuals showed the same melting point curve and melting point peak results as unmethylated DNA, indicating that blood cells from normal individuals did not show the methylation level for the biomarker according to an example of the present application.

[0204]

[0205] Example 9. Diagnosis of liver cancer using blood samples

[0206] (1) Analysis of the accuracy of liver cancer diagnosis (1)

[0207] cfDNA extracted from the plasma of 81 healthy individuals and 319 HCC patients was converted to sulfite to prepare samples for MS-HRM analysis. To measure the methylation level of Marker 1 in each sample according to an example of the present application, a PCR mixture was prepared using the primers in Table 4 as follows (based on 1 rxn):

[0208] Master Mix (2X): 12.5 μL (Final Conc. 1X)

[0209] EvaGreen (20X): 1.25 μL (Final Conc. 1X)

[0210] Methylated Forward Primer (10 uM): 1 μL (Final Conc. 0.4 uM)

[0211] Methylated Reverse Primer (10 uM): 1 μL (Final Conc. 0.4 uM)

[0212] Unmethylated Forward Primer (10 uM): 0.5 μL (Final Conc. 0.2 uM)

[0213] NFW (nuclease-free water): 5.75 μL

[0214] Total: 22 μL

[0215] 3 μL of a 0.33 ng / μL control nucleic acid sample was dispensed into each well, and PCR reaction and HRM analysis were performed under the following conditions:

[0216] 95℃ 5 minutes / 95℃ 20 seconds - 69℃ 40 seconds (20 cycles, starting at 69℃ and decreasing by 0.3℃ per cycle to end at 63℃): PCR reaction

[0217] 95℃ 20 seconds - 63℃ 40 seconds (40 cycles, constant at 63℃): PCR reaction

[0218] 63℃ 5 minutes / 60℃ - 95℃ (increase by 0.2℃ and measure fluorescence value after 10 seconds of reaction): HRM analysis

[0219] The MS-HRM analysis method established in Example 5 was applied to each sample, and the AUMC was derived from the normalized melting point curve. Based on the AUMC of 81 healthy individuals, 97 thPercentile was set as the cut-off, and the AUMC distribution of healthy people and patients with early, middle, and late liver cancer is shown as a boxplot in Figure 9a (A). In addition, the methylation level was quantified using the following mathematical formula 1 based on the AUMC of the 100% methylated control sample and the 100% unmethylated control sample, and is shown in Figure 9a (B). At this time, if the methylation level was less than 0, it was calculated as 0, and if the methylation level was 100 or higher, it was calculated as 100. The cut-off value set in Figure 9a is indicated by a dotted line.

[0220] [Mathematical Formula 1]

[0221] Methylation level = (AUMC sample - AUMC unmet.Ctrl ) / (AUMC Met.Ctrl - AUMC Unmet.Ctrl )

[0222] AUMC sample :AUMC value of the sample

[0223] AUMC unmet.Ctrl :AUMC value of 100% unmethylated control sample

[0224] AUMC Met.Ctrl :AUMC value of 100% methylated control sample

[0225]

[0226] As shown in Fig. 9a, the distribution of AUMC between the healthy group and the HCC patient group showed a statistically significant difference based on a t-test, confirming that the methylation level of marker 1 according to an example of the present application accurately predicts the risk of developing liver cancer.

[0227]

[0228] (2) Analysis of the accuracy of liver cancer diagnosis (2)

[0229] A total of 420 clinical specimens (healthy control group; 89 subjects, high-risk group; 196 subjects, liver cancer group; 135 subjects) were prepared using the same method as in (1) of Example 9, and the AUMC analysis results using the primers in Table 5 are shown in Fig. 9b. As shown in Fig. 9b, a statistically significant increase in AUMC values ​​(the degree of methylation in the specimens) was confirmed in the early-stage liver cancer group (BCLC 0-A) and the late-stage liver cancer group (BCLC BD) compared to the control group.

[0230] In addition, a cut-off of 95% specificity was set based on the TS-AUMC value observed in the healthy control group in the clinical data based on the produced blood sample, and based on this, the sensitivity and specificity were calculated by calculating the sensitivity by BCLC stage of liver cancer patients, and the results are shown in Table 6. As shown in Table 6, Marker 1, which is a biomarker according to an example of the present application, had the effect of showing a sensitivity of 50% or more and 70% or more in early and late liver cancer patients, respectively, at a high specificity level, and was able to diagnose liver cancer with excellent accuracy.

[0231] TypeSensitivitySpecifityStageBCLC 0BCLC ABCLC BBCLC C-DTotalHealthyPositive8201841875Negative6207154884Total1440255613589Se. | Sp.57.1%50.0%72.0%73.2%64.4%94.4%

[0232]

[0233] Example 10. Comparison with conventional liver cancer diagnostic markers

[0234] HCC patients were classified into Early and Late Stages according to BCLC Stage (Early; BCLC 0 & A, Late; BCLC B, C & D). The diagnostic ability of the analysis method developed in this application was compared with the conventional liver cancer screening method, AFP level confirmation, according to the stage of HCC patients. 97 of the AUMC values ​​confirmed in 81 healthy individuals th The sensitivity and specificity for determining HCC positive / negative based on percentile and AFP 20 or higher are shown in Table 7.

[0235] MarkerTotalEarlySe Early LateSe Late HCCSe Total HealthySpmarker 1Positive11862.4%10177.7%21968.7%396.3%Negative712910078Total18913031981AFPPositive6132.3%8363.9%14445.1%--N egative12847175-Total18913031981CombinationPositive13772.5%11386.9%25078.4%--Negative521769-Total18913031981

[0236] As shown in Table 7, the diagnostic sensitivity of the biomarker-based liver cancer screening method according to an example of the present application was confirmed to be about 23.6% higher than that of the conventional AFP test for liver cancer in all liver cancer patients, and in particular, the sensitivity was confirmed to be about 30.1% higher than that of the AFP test in early liver cancer patients. In addition, it was confirmed that the overall diagnostic sensitivity was significantly increased when the biomarker-based liver cancer screening method according to an example of the present application and the AFP test were performed in parallel, and this can be helpful in diagnosing liver cancer in conjunction with the conventional biopsy method in terms of being a blood-based liquid biopsy.

[0237]

[0238] Example 11. Improved diagnostic performance by combining biomarkers.

[0239] (1) Diagnosis of liver cancer by combination of marker 1 and marker 2

[0240] HCC patients were classified into Early and Late Stages according to BCLC Stage (Early; BCLC 0 & A, Late; BCLC B, C & D). The diagnostic ability of liver cancer when combining markers 1 and 2 according to an example of the present application was compared according to the stage of HCC patients and is shown in Table 8.

[0241] MarkerTotalEarlySe Early LateSe Late HCCSe Total HealthySpmarker 1Positive12163.0%10377.4%22468.9%396.3%Negative713010179Total19213332582marker 2Positive7137.0%9067.7%16149.5%198.8%Negative1214316481Total19213332582Combi nationPositive14374.5%11586.5%25879.4%495.1%Negative49186778Total19213332582

[0242] As shown in Table 8, when marker 1 according to an example of the present application was used, superior sensitivity was confirmed in all liver cancer stages compared to marker 2, and additionally, when the two markers were used in combination, the sensitivity increased by more than 10% while maintaining the same specificity, showing that it is possible to improve liver cancer diagnostic performance.

[0243]

[0244] (2) Diagnosis of liver cancer using marker 1 and various biomarker combinations

[0245] We tested whether combining biomarker 1, an example of the present application, with various biomarkers, such as AFP, age, and sex, could improve the diagnostic accuracy of liver cancer. A conventional MS-HRM method served as a control group. Specifically, among the generated data, logistic regression analysis was performed using the glm() function in R based on samples with all age, sex, and AFP test values. Combining this with the TS-AUMC value, a diagnostic prediction model was constructed, and the roc() function was used to verify clinical performance.

[0246] As shown in Fig. 10, marker 1, a biomarker according to an example of the present application, showed excellent liver cancer diagnostic ability even when used alone, and when combined with AFP test method, age information, and gender information to predict liver cancer group based on a logistic regression model, it showed a synergistic effect with a maximum AUC increasing to 0.9524 (0.9309-0.9740).

[0247]

[0248] Example 12. Liver cancer specificity of target methylation sites

[0249] In order to confirm the liver cancer specificity of the marker 1 target region according to an example of the present application, the average methylation degree was analyzed by cancer type using the methylation data of the TCGA and GEO databases used in Example 4.

[0250] Specifically, the results of checking the methylation level for each data set as a heatmap using the ggplot2 R package in R software are shown in Figure 11 (X-axis: sample, Y-axis: Probe ID in the LDHB gene). In FIG. 11, the X-axis represents normal and cancer tissue samples of 23 cancer data sets including liver cancer, the Y-axis represents biomarkers, the color of the matrix represents the degree of methylation, and the boxed portion in the region where the Probe ID is indicated represents CGI regions included in marker 1 according to an example of the present application, including regions 21810279 to 21810280, 21810450 to 21810451, 21810458 to 21810459, 21810489 to 21810490, 21810600 to 21810601, 21810750 to 21810751, 21810759 to 21810760, and 21810791 to The CpG site located at the 21810792nd sequence is shown, and the shaded portion indicates the target site of the 21810750th to 21810751st CGI.

[0251] As shown in Fig. 11, the CGI (CpG island) region included in the sequence region from 21810279 to 21810792 of chromosome 12 was hypermethylated only in liver cancer samples, while normal liver and other cancers showed a hypomethylated pattern, and therefore, high liver cancer specificity can be secured through the degree of methylation of the target region. On the other hand, other regions did not show a methylation status specific to liver cancer, such as cg26362257 (sequences 21788425 to 21788426 of chromosome 12), which were hypermethylated in the majority of samples, or cg03243946 (sequences 21811034 to 21811035 of chromosome 12) and cg10195295 (sequences 21809973 to 21809974 of chromosome 12), which were hypermethylated in pancreatic adenocarcinoma (PAAD) and prostate adenocarcinoma (PRAD), including cholangiocarcinoma (CHOL).

[0252] Therefore, as a result of checking the average methylation value in each cancer type, it was confirmed that only the marker 1 region according to an example of the present application had liver cancer specificity.

[0253]

[0254] Example 13. Confirmation of the diagnostic ability of biomarkers for liver cancer.

[0255] CFDNA extracted from the plasma of 210 healthy individuals, 176 high-risk patients, and 133 liver cancer patients was converted to sulfite to prepare samples for MS-HRM analysis. Exemplary sequences of primer sets designed for marker 2 are shown in Table 9, and exemplary sequences of primer sets designed for marker 3 are shown in Table 10. In each primer sequence, the sites corresponding to CpG or non-CpG cytosines of marker 3 are indicated in capital letters, and the other bases are indicated in lowercase letters.

[0256] nameSeq (5'->3')SEQ ID NO.Methylated Forward Primer for marker 2TTatggCGggTTtgggTTtgggTtT13Methylated Reverse Primer for marker 2caAcccctAAcaAatAatAcaAcC14

[0257] nameSeq (5'->3')SEQ ID NO.Methylated Forward Primer for marker 3GgatTagggagtggTttgtaaT15Methylated Reverse Primer for marker 3ccCGctctcttcttCGtA16Unmethylated Reverse Primer for marker 3acccCActctcttcttCAtA17

[0258] To measure the methylation level of marker 2 according to an example of the present application in each sample, a PCR Mixture was prepared as in Example 5 using the primers in Table 7, and PCR reaction and HRM analysis were performed under the same conditions.

[0259] Additionally, to measure the methylation level of marker 3 according to an example of the present application in each sample, a PCR Mixture was prepared as follows using the primers in Table 8 (based on 1 rxn):

[0260] Master Mix (2X): 12.5 μL (Final Conc. 1X)

[0261] EvaGreen (20X): 1.25 μL (Final Conc. 1X)

[0262] Methylated Forward Primer (10 uM): 1 μL (Final Conc. 0.4 uM)

[0263] Methylated Reverse Primer (10 uM): 1 μL (Final Conc. 0.4 uM)

[0264] Unmethylated Reverse Primer (10 uM): 0.5 μL (Final Conc. 0.2 uM)

[0265] NFW (nuclease-free water): 5.75 μL

[0266] Total: 22 μL

[0267] 3 μL of a 0.33 ng / μL control nucleic acid sample was dispensed into each well, and PCR reaction and HRM analysis were performed under the following conditions:

[0268] 95℃ 5 minutes / 95℃ 20 seconds - 61℃ 30 seconds - 72℃ 30 seconds (50 Cycles): PCR reaction

[0269] 72℃ 5 minutes / 60℃ - 95℃ (increase by 0.2℃ and measure fluorescence value after 10 seconds of reaction): HRM analysis

[0270] The MS-HRM analysis method established in Example 5 was applied to each sample, and the AUMC was derived from the normalized melting point curve. The 95th percentile was set as the cutoff based on the AUMC of 210 healthy individuals, and the distribution of AUMCs among healthy individuals, high-risk patients, and liver cancer patients is shown in boxplots in Figure 12. The cutoff values ​​established in Figure 12 are indicated by dotted lines.

[0271] As shown in Fig. 12, a statistically significant AUMC distribution was observed in the liver cancer patient group based on a t-test among the healthy person group, high-risk patient group, and liver cancer patient group, confirming that the methylation levels of markers 2 and 3 according to an example of the present application accurately predict the risk of developing liver cancer.

Claims

1. A composition for predicting the risk of developing liver cancer, comprising a preparation capable of measuring the methylation level of at least one CpG site included in the sequence region 21810279 to 21810792 of human chromosome 12 in a biological sample.

2. A composition according to claim 1, wherein the CpG site comprises a CpG site located at sequences 21810750 to 21810751 of human chromosome 12.

3. A composition according to claim 1, wherein the region has a sequence represented by sequence number 1.

4. A composition according to claim 1, further comprising an agent capable of measuring the methylation level of at least one CpG site included in the sequence region 29298021 to 29298631 of human chromosome 17 in the biological sample; and / or an agent capable of measuring the methylation level of at least one CpG site included in the sequence region 19738547 to 19739846 of human chromosome 19 in the biological sample.

5. In the fourth paragraph, at least one CpG site included in the sequence region 29298021 to 29298631 of the human chromosome 17 comprises a CpG site located in the sequence region 29298115 to 29298116, 29298118 to 29298119, 29298124 to 29298125, 29298136 to 29298137, 29298142 to 29298143, or 29298184 to 29298185 of the human chromosome 17, A composition, wherein at least one CpG site included in the sequence region 19738547 to 19739846 of human chromosome 19 comprises a CpG site located in the sequence region 19739407 to 19739408 of human chromosome 19.

6. A composition according to claim 4, wherein the sequence region 29298021 to 29298631 of the human chromosome 17 has a sequence represented by SEQ ID NO: 2, and the sequence region 19738547 to 19739846 of the human chromosome 19 has a sequence represented by SEQ ID NO:

3.

7. A composition according to claim 1, further comprising a preparation capable of measuring the concentration of alpha fetoprotein (AFP) in the biological sample.

8. A composition according to claim 1, wherein the preparation is a primer for amplifying a target methylation site of the sequence region.

9. In paragraph 8, the primer includes a forward primer and a reverse primer, One of the forward primer and the reverse primer comprises a methylated primer and a non-methylated primer, The above methylation primer comprises at least one CpG recognition site that recognizes a CpG sequence included in a predetermined length sequence including the target methylation site, The above unmethylated primer comprises at least one TpG recognition site that recognizes a TpG sequence included in a predetermined length sequence including the target methylation site, A composition wherein a TpG sequence of a predetermined length sequence including the target methylation site is converted from an unmethylated CpG sequence of a predetermined length sequence including the target methylation site.

10. A composition according to claim 9, wherein the TpG sequence is converted by an agent that differently modifies a methylated CpG sequence and an unmethylated CpG sequence.

11. A composition according to claim 10, wherein the modifying agent converts an unmethylated cytosine residue into thymine.

12. A composition according to claim 1, wherein the biological sample is at least one selected from the group consisting of blood, plasma, serum, platelets, tissue, cells, feces, and urine.

13. A composition according to claim 1, wherein the sequence region is contained in cell free DNA (cfDNA).

14. In the first paragraph, the liver cancer is hepatocellular carcinoma (HCC).

15. A kit for predicting the risk of developing liver cancer, comprising a composition according to any one of claims 1 to 14.

16. A method for providing information for predicting the risk of developing liver cancer, comprising the step of measuring the methylation level of at least one CpG site included in the sequence region 21810279 to 21810792 of human chromosome 12 in a biological sample isolated from a subject.

17. A method according to claim 16, wherein the CpG site comprises CpG sites 21810750 to 21810751 of human chromosome 12.

18. A method according to claim 16, wherein the region has a sequence represented by sequence number 1.

19. A method according to claim 16, further comprising: a step of measuring the methylation level of at least one CpG site included in the sequence region 29298021 to 29298631 of human chromosome 17 in the biological sample; and / or a step of measuring the methylation level of at least one CpG site included in the sequence region 19738547 to 19739846 of human chromosome 19 in the biological sample.

20. In claim 19, at least one CpG site included in the sequence region 29298021 to 29298631 of human chromosome 17 comprises a CpG site located in the sequence region 29298115 to 29298116, 29298118 to 29298119, 29298124 to 29298125, 29298136 to 29298137, 29298142 to 29298143, or 29298184 to 29298185 of human chromosome 17, A method, wherein at least one CpG site included in the sequence region 19738547 to 19739846 of the human chromosome 19 comprises a CpG site located in the sequence 19739407 to 19739408 of the human chromosome 19.

21. A method according to claim 19, wherein the sequence region 29298021 to 29298631 of the human chromosome 17 has a sequence represented by SEQ ID NO: 2, and the sequence region 19738547 to 19739846 of the human chromosome 19 has a sequence represented by SEQ ID NO:

3.

22. A method according to claim 16, further comprising: a step of measuring the concentration of alpha fetoprotein (AFP) in the biological sample; a step of collecting gender information of the subject; and / or a step of collecting age information of the subject.

23. A method according to claim 16, wherein the methylation level is measured using a primer for amplifying a target methylation site of the sequence.

24. In paragraph 23, the primer includes a forward primer and a reverse primer, One of the forward primer and the reverse primer comprises a methylated primer and a non-methylated primer, The above methylation primer comprises at least one CpG recognition site that recognizes a CpG sequence included in a predetermined length sequence including the target methylation site, The above unmethylated primer comprises at least one TpG recognition site that recognizes a TpG sequence included in a predetermined length sequence including the target methylation site, A method wherein a TpG sequence of a predetermined length sequence including the target methylation site is converted from an unmethylated CpG sequence included in the predetermined length sequence including the target methylation site.

25. A method according to claim 16, further comprising a step of quantifying the methylation level of the CpG site.

26. In the 25th paragraph, the quantifying step is a method in which the degree of methylation of the CpG site is quantified by comparing the AUC (Area under the curve) of the normalized melting curve of the biological sample; a sample in which the CpG site is 100% methylated; and a sample in which the CpG site is 100% unmethylated.

27. In the 16th paragraph, a step of obtaining a melting curve of the biological sample; A step of obtaining a normalized melt curve of a biological sample for which the content ratio of the sequence in which the CpG site is methylated and the sequence in which the CpG site is unmethylated is known; and A method further comprising a step of quantifying the degree of methylation of the CpG site by comparing the melting curve of the biological sample and the normalized melting curve.

28. A method according to claim 16, further comprising a step of comparing the methylation level with the methylation level of a control group.

29. A method according to claim 16, further comprising a step of comparing the methylation level with the methylation level of a normal control group, wherein if the methylation level is higher than the methylation level of the normal control group, information is provided that the subject has a risk of developing liver cancer.

30. A method according to claim 16, wherein the biological sample is at least one selected from the group consisting of blood, plasma, serum, platelets, tissue, cells, feces, and urine.

31. A method according to claim 16, wherein the sequence is contained in cell free DNA (cfDNA).

32. A method according to claim 16, wherein the liver cancer is hepatocellular carcinoma (HCC).